Disclaimer: This comprehensive medical reference is intended for informational and educational purposes only, and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment, taking into account individual patient circumstances, local guidelines, and the most current evidence. Drug dosages and treatment regimens are provided as general guidance and may require adjustment based on patient factors, comorbidities, and monitoring. Consult official prescribing information for all medications.

Diabetes Mellitus

Overview

• Definition: Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by sustained hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.
• Epidemiology:
  • Global Prevalence: Approximately 537 million adults (20-79 years) worldwide were living with diabetes in 2021, and this number is projected to rise to 643 million by 2030 and 783 million by 2045 (IDF Diabetes Atlas 10th edition).
  • United States: As of 2019, 37.3 million Americans (11.3% of the population) have diabetes, with 28.7 million diagnosed and 8.5 million undiagnosed. Approximately 96 million adults (38% of the adult population) have prediabetes (CDC National Diabetes Statistics Report).
  • Incidence: In 2019, 1.5 million new cases of diabetes were diagnosed among U.S. adults.
  • Demographics: Type 2 DM is more prevalent in older adults, certain ethnic groups (e.g., African Americans, Hispanic/Latino, American Indian/Alaska Native, Asian Americans), and individuals with lower socioeconomic status. Type 1 DM typically presents in childhood or adolescence but can occur at any age.
• Classification:
  • Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of the pancreatic beta cells, leading to absolute insulin deficiency. Accounts for 5-10% of all diagnosed diabetes cases.
    • Subtypes: Immune-mediated (most common) and idiopathic.
  • Type 2 Diabetes Mellitus (T2DM): Characterized by progressive loss of beta-cell insulin secretion, frequently on the background of insulin resistance. Accounts for 90-95% of all diagnosed cases.
  • Gestational Diabetes Mellitus (GDM): Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation.
  • Other Specific Types of Diabetes:
    • Monogenic Diabetes Syndromes: Such as Neonatal Diabetes or Maturity-Onset Diabetes of the Young (MODY).
    • Diseases of the Exocrine Pancreas: Cystic fibrosis, pancreatitis, hemochromatosis.
    • Drug- or Chemical-Induced Diabetes: Glucocorticoids, post-transplant diabetes (e.g., tacrolimus, cyclosporine), atypical antipsychotics.
    • Endocrinopathies: Cushing's syndrome, acromegaly, pheochromocytoma, glucagonoma.

Pathophysiology

• Mechanism:
  • Type 1 DM: An autoimmune process (cellular and humoral immunity) targets and destroys the insulin-producing beta cells in the pancreatic islets of Langerhans. This leads to a progressive decline in insulin secretion, eventually resulting in absolute insulin deficiency. Genetic susceptibility (e.g., HLA DR3/DR4) and environmental triggers (e.g., viral infections) are implicated.
  • Type 2 DM: Involves two main defects:
    1. Insulin Resistance: Peripheral tissues (muscle, liver, adipose tissue) fail to respond adequately to normal insulin levels. This leads to increased glucose production by the liver and reduced glucose uptake by muscle and fat cells.
    2. Beta-Cell Dysfunction: Initially, pancreatic beta cells compensate for insulin resistance by increasing insulin secretion (hyperinsulinemia). Over time, they become exhausted and progressively lose their ability to secrete sufficient insulin, leading to relative insulin deficiency. This is often accompanied by impaired incretin effect (reduced GLP-1 and GIP secretion/action).
  • Gestational Diabetes: Primarily due to increased insulin resistance during pregnancy caused by placental hormones (e.g., human placental lactogen, progesterone, cortisol, prolactin). The maternal pancreas may not be able to produce enough insulin to overcome this resistance.
• Risk Factors:
  • Type 1 DM:
    • Family history of T1DM.
    • Genetic susceptibility (e.g., HLA-DR3/DR4, specific non-HLA genes).
    • Certain environmental factors (e.g., viral infections like enteroviruses, early exposure to cow's milk, rapid growth during childhood).
    • Presence of autoantibodies (e.g., GADA, ICA, IA-2A, ZnT8A).
  • Type 2 DM:
    • Overweight or Obesity: BMI ≥25 kg/m² (≥23 kg/m² in Asian Americans).
    • Physical Inactivity: Sedentary lifestyle.
    • Age: ≥45 years.
    • Family History: First-degree relative with T2DM.
    • Race/Ethnicity: African American, Hispanic/Latino, American Indian/Alaska Native, Asian American, Pacific Islander.
    • History of GDM: Or having a baby weighing >9 lb (4.1 kg).
    • Hypertension: Blood pressure ≥140/90 mmHg or on medication for hypertension.
    • Dyslipidemia: HDL cholesterol <35 mg/dL (0.90 mmol/L) and/or triglycerides >250 mg/dL (2.82 mmol/L).
    • Polycystic Ovary Syndrome (PCOS).
    • History of Cardiovascular Disease (CVD).
    • Insulin Resistance States: e.g., severe obesity, acanthosis nigricans.
    • Prediabetes: (A1C 5.7–6.4%, FPG 100–125 mg/dL, or 2-h PG 140–199 mg/dL).
• Protective Factors:
  • Type 1 DM: No established protective factors. Research is ongoing into immune modulation strategies.
  • Type 2 DM:
    • Healthy Lifestyle: Maintaining a healthy body weight (BMI 18.5-24.9 kg/m²).
    • Regular Physical Activity: At least 150 minutes of moderate-intensity aerobic activity per week.
    • Balanced Diet: Rich in whole grains, fruits, vegetables, lean protein, and low in saturated fats and refined sugars.
    • Smoking Cessation:
    • Moderate Alcohol Consumption: Or abstention.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: (Often more prominent in T1DM, can be subtle in T2DM)
  • Polyuria: Frequent urination due to osmotic diuresis caused by glycosuria.
  • Polydipsia: Increased thirst, a compensatory response to dehydration from polyuria.
  • Polyphagia: Increased hunger, especially in T1DM, due to inability of glucose to enter cells for energy.
  • Unexplained Weight Loss: More common in T1DM (due to catabolism of fat and protein) but can occur in T2DM.
• Early Signs:
  • Fatigue, lethargy.
  • Blurred vision (due to osmotic changes in the lens).
  • Numbness or tingling in extremities (early neuropathy).
  • Recurrent infections (e.g., skin infections, urinary tract infections, candidiasis) due to impaired immune function and glycosuria.
  • Slow wound healing.
• Advanced Signs:
  • Persistent or worsening neuropathy (pain, numbness, weakness, foot deformities).
  • Symptoms of cardiovascular disease (angina, claudication, dyspnea).
  • Renal symptoms (edema, foamy urine from proteinuria).
  • Vision loss (advanced retinopathy).
  • Signs of peripheral artery disease (non-healing ulcers, critical limb ischemia).
  • Signs of autonomic neuropathy (gastroparesis, orthostatic hypotension, erectile dysfunction).
• Atypical Presentations:
  • Diabetic Ketoacidosis (DKA) or Hyperosmolar Hyperglycemic State (HHS) as the initial presentation, particularly in T1DM and sometimes in T2DM.
  • Silent myocardial infarction.
  • Depression, cognitive dysfunction.
  • Obesity with no classic symptoms (T2DM often diagnosed incidentally).
  • Recurrent vaginal candidiasis (women).

Physical Examination

• Inspection:
  • General: Obesity (T2DM), cachexia (severe T1DM or advanced T2DM), signs of dehydration.
  • Skin:
    • Acanthosis nigricans (dark, velvety patches, often in skin folds) – sign of insulin resistance.
    • Skin tags.
    • Xanthomas (eruptive, tendinous, planar) – sign of dyslipidemia.
    • Necrobiosis lipoidica diabeticorum (yellowish-red plaques, often on shins).
    • Diabetic dermopathy (shin spots).
    • Fungal infections (candidiasis, tinea).
    • Poor wound healing, ulcers (especially on feet).
  • Eyes: Early cataracts, signs of retinopathy (hemorrhages, exudates, neovascularization, cotton wool spots on fundoscopy).
  • Feet: Deformities (Charcot arthropathy, hammer toes), calluses, ulcers, amputations, signs of peripheral artery disease (trophic changes, pallor, hair loss, dependent rubor).
• Palpation:
  • Pulses: Diminished or absent peripheral pulses (femoral, popliteal, dorsalis pedis, posterior tibial) indicating peripheral artery disease.
  • Temperature: Cold extremities (ischemia).
  • Neurological: Monofilament test for sensory neuropathy, reduced vibratory sensation, altered proprioception.
• Special Tests:
  • Fundoscopy: Examination of the retina for signs of diabetic retinopathy.
  • Monofilament Test: Assesses protective sensation in the feet for diabetic neuropathy.
  • Vibration Perception Threshold (VPT): Using a tuning fork (128 Hz) to assess neuropathy.
  • Ankle-Brachial Index (ABI): To screen for peripheral artery disease (ABI <0.9).
  • Orthostatic Blood Pressure Measurement: To assess for autonomic neuropathy.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptoms: Presence, duration, and severity of polyuria, polydipsia, polyphagia, weight changes, fatigue, blurred vision, numbness/tingling, recurrent infections.
  • Risk Factors: Family history of diabetes, personal history of GDM, large-for-gestational-age infant, hypertension, dyslipidemia, PCOS, history of CVD.
  • Lifestyle: Diet (typical food intake, sugar-sweetened beverages), physical activity level, smoking, alcohol use.
  • Comorbidities: Heart disease, kidney disease, neurological issues, eye problems, foot issues.
  • Medications: Current medications, especially those that can affect glucose (e.g., steroids, diuretics, atypical antipsychotics).
  • Social History: Access to healthy food, ability to exercise, support system.
• Red Flags:
  • Acute Symptoms: Rapid onset of severe polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain, altered mental status – suggestive of DKA or HHS, requiring urgent evaluation.
  • Unexplained persistent hyperglycemia
  • Recurrent infections or non-healing wounds.
  • Symptoms of severe hypoglycemia: Confusion, seizures, unconsciousness, if already on treatment.

Laboratory Tests

Diagnosis of diabetes is made by plasma glucose criteria, either fasting, 2-hour post-glucose load, or random, or by HbA1c. Testing for T2DM should be considered in all adults who are overweight or obese (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) and have one or more additional risk factors for diabetes. For all people, testing should begin at age 35 years. - First-Line/Confirmatory: (According to ADA guidelines, confirmed by repeat testing on a separate day unless clear hyperglycemia with acute metabolic decompensation) * Fasting Plasma Glucose (FPG): Fasting for at least 8 hours. * Normal: <100 mg/dL (5.6 mmol/L) * Prediabetes (Impaired Fasting Glucose - IFG): 100-125 mg/dL (5.6-6.9 mmol/L) * Diabetes: ≥126 mg/dL (7.0 mmol/L) * Oral Glucose Tolerance Test (OGTT): 2-hour Plasma Glucose (2hPG) after a 75-g anhydrous glucose load. * Normal: <140 mg/dL (7.8 mmol/L) * Prediabetes (Impaired Glucose Tolerance - IGT): 140-199 mg/dL (7.8-11.0 mmol/L) * Diabetes: ≥200 mg/dL (11.1 mmol/L) * Glycated Hemoglobin (HbA1c): Reflects average blood glucose over the past 2-3 months. Must be performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized to the DCCT assay. * Normal: <5.7% * Prediabetes: 5.7-6.4% * Diabetes: ≥6.5% * Note: HbA1c may be unreliable in conditions affecting red blood cell turnover (e.g., severe anemia, hemoglobinopathies, recent blood transfusion, pregnancy). * Random Plasma Glucose (RPG): * Diabetes: ≥200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or hyperglycemic crisis. No confirmatory testing needed in this scenario.

• Monitoring: (Once diabetes is diagnosed)
  • HbA1c: Every 3 months if not at glycemic goal or if therapy has changed; at least twice a year if at goal and stable.
  • Lipid Panel: Annually, or more frequently if abnormalities are present or therapy is initiated/changed. Targets: LDL-C <70 mg/dL (1.8 mmol/L) or <55 mg/dL (1.4 mmol/L) for high-risk patients.
  • Kidney Function:
    • Serum Creatinine and eGFR: Annually.
    • Urine Albumin-to-Creatinine Ratio (UACR): Annually for T1DM patients with duration ≥5 years, all T2DM patients, and all patients with hypertension. (Normal <30 mg/g creatinine).
  • Liver Function Tests: Consider for patients with NAFLD risk or on certain medications.
  • Thyroid-Stimulating Hormone (TSH): Especially in T1DM (due to increased risk of autoimmune thyroid disease) or if symptoms suggest thyroid dysfunction.
  • Vitamin B12 levels: Annually in patients on metformin, especially if symptoms of neuropathy or anemia.
  • Electrolytes: If on diuretics or with kidney disease.
  • C-peptide and Autoantibodies (GADA, ICA, IA-2A, ZnT8A): To differentiate T1DM from T2DM, particularly in ambiguous cases (e.g., lean adults presenting with DKA, suspected LADA). C-peptide can assess residual beta-cell function.

Imaging

Imaging is not typically used for the diagnosis of diabetes itself but is crucial for screening, diagnosing, and monitoring its complications. - Recommended (for complications screening/diagnosis): * Fundoscopy (Dilated Retinal Exam): Performed by an ophthalmologist or optometrist. Annually for T1DM patients 5 years after diagnosis, and annually at diagnosis for T2DM patients. More frequently if retinopathy is present. * Electrocardiogram (ECG): As part of cardiovascular risk assessment, especially in patients with risk factors or symptoms. * Foot X-rays/MRI: To evaluate for osteomyelitis, Charcot arthropathy, or other bony abnormalities in patients with foot ulcers or deformities. * Carotid Ultrasound: To screen for carotid artery disease in high-risk individuals with CVD or multiple risk factors. * Renal Ultrasound: If nephropathy is rapidly progressing or if obstruction is suspected. - Advanced (when needed): * Cardiac Stress Testing (ECG or Imaging-based): For symptomatic patients with suspected CAD or for risk stratification in asymptomatic patients with very high risk (e.g., multiple risk factors, advanced nephropathy, peripheral artery disease). * CT Angiography/MRI Angiography: For detailed assessment of peripheral or coronary artery disease. * MRI of the Brain: In case of unexplained neurological symptoms or stroke.

Management

Acute Management

• Immediate:
  • Severe Hypoglycemia (Glucose <70 mg/dL (3.9 mmol/L) with symptoms, or <54 mg/dL (3.0 mmol/L) asymptomatic):
    • Conscious patient: Ingest 15-20g fast-acting carbohydrate (e.g., 4 oz juice, glucose tablets). Recheck glucose in 15 min. Repeat until glucose >70 mg/dL.
    • Unconscious/Unable to swallow: Administer glucagon (1 mg IM/SC) or IV dextrose (25-50 mL of D50W).
  • Diabetic Ketoacidosis (DKA) or Hyperosmolar Hyperglycemic State (HHS):
    • Fluid Resuscitation: Initiate IV fluids (0.9% NaCl) to correct dehydration.
    • Insulin Therapy: Continuous IV regular insulin infusion (e.g., 0.1 U/kg/hr) to lower glucose and suppress ketogenesis.
    • Electrolyte Management: Monitor and replace potassium (crucial before/during insulin therapy), phosphate, magnesium.
    • Acid-Base Balance: Address acidosis in DKA (usually resolves with insulin and fluids, bicarbonate rarely indicated).
    • Identify and Treat Precipitating Factors: Infection, inadequate insulin, MI, stroke.
• Stabilization:
  • Close monitoring of glucose, electrolytes, fluid balance, mental status.
  • Transition from IV to subcutaneous insulin once stable, glucose is controlled, and acidosis/ketosis resolved (DKA) or osmolality normalized (HHS).
• Emergency:
  • Any patient presenting with DKA or HHS requires immediate admission to an intensive care unit (ICU) for close monitoring and aggressive management.
  • Severe hypoglycemia leading to loss of consciousness or seizures also constitutes an emergency requiring immediate intervention.

Chronic Management

The overarching goal is to prevent complications by achieving and maintaining glycemic control, managing cardiovascular risk factors, and regular screening for complications. - Glycemic Targets: (Individualized based on age, comorbidities, duration of diabetes, risk of hypoglycemia) * HbA1c: * General non-pregnant adults: <7.0% (53 mmol/mol) * Younger/healthier/newly diagnosed: <6.5% (48 mmol/mol) to reduce long-term complications. * Elderly/frail/multiple comorbidities/history of severe hypoglycemia/limited life expectancy: <8.0% (64 mmol/mol). * Fasting Plasma Glucose: 80-130 mg/dL (4.4-7.2 mmol/L) * Peak Postprandial Glucose: <180 mg/dL (10.0 mmol/L) - Pharmacological: * Type 1 DM: Requires exogenous insulin for survival. * Insulin Regimens: * Basal-Bolus: Daily basal insulin (e.g., glargine, detemir, degludec) to cover hepatic glucose production and bolus (prandial) rapid-acting insulin (e.g., aspart, lispro, glulisine) before meals to cover carbohydrate intake. * Continuous Subcutaneous Insulin Infusion (CSII) - Insulin Pump: Delivers continuous basal insulin and user-initiated boluses. Offers flexibility and tighter control. * Dosage: Highly individualized, often starting with 0.5-0.7 U/kg/day, with approximately 50% as basal and 50% as bolus. Insulin-to-carbohydrate ratios (ICR) and insulin sensitivity factors (ISF) are used for bolus dosing. * Adjunctive Therapies: Pramlintide (amylin analog) for postprandial glucose control. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) can be considered as adjunctive therapy in T1DM for glycemic control and potential cardiorenal benefits, with careful monitoring for euglycemic DKA. * Type 2 DM: * Metformin: First-line therapy, unless contraindicated. * Mechanism: Decreases hepatic glucose production, improves insulin sensitivity. * Dosage: Start 500 mg once or twice daily, titrate up to 1000 mg twice daily (maximum 2550 mg/day). Take with food to minimize GI side effects. * Benefits: Effective, low hypoglycemia risk, weight-neutral/modest weight loss, potential cardiovascular benefits, inexpensive. * Side Effects: GI upset (nausea, diarrhea), Vitamin B12 deficiency, lactic acidosis (rare, risk increased with renal impairment, acute heart failure, liver disease, alcohol abuse). * Contraindications: eGFR <30 mL/min/1.73m². Use with caution if eGFR 30-45 mL/min/1.73m². * GLP-1 Receptor Agonists (GLP-1 RAs): (e.g., exenatide, liraglutide, dulaglutide, semaglutide) * Mechanism: Enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, promotes satiety. * Benefits: Significant A1c reduction, substantial weight loss, proven cardiovascular and renal benefits (liraglutide, dulaglutide, semaglutide). Low hypoglycemia risk. * Side Effects: Nausea, vomiting, diarrhea, pancreatitis (rare), thyroid C-cell tumors (rodent data, avoid in medullary thyroid carcinoma history). * Dosage: Varies by agent (once daily, once weekly injections; oral semaglutide). * Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: (e.g., empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) * Mechanism: Blocks glucose reabsorption in the renal tubules, leading to increased urinary glucose excretion. * Benefits: A1c reduction, weight loss, blood pressure reduction, proven cardiovascular (HF) and renal benefits for all agents, CVD risk reduction (empagliflozin, canagliflozin, dapagliflozin). Low hypoglycemia risk. * Side Effects: Genitourinary infections (yeast infections, UTIs), polyuria, dehydration, hypotension, euglycemic DKA (rare), lower limb amputations (canagliflozin, caution). * Dosage: Varies by agent, typically 10-25 mg once daily. Renal dosing adjustments are crucial. * Dual GIP/GLP-1 Receptor Agonist (Tirzepatide): * Mechanism: Activates both GIP and GLP-1 receptors. * Benefits: Superior A1c and weight reduction compared to GLP-1 RAs alone. Emerging data suggests cardiovascular benefits. * Side Effects: Similar to GLP-1 RAs (GI upset). * Dosage: Once weekly subcutaneous injection, titrated. * DPP-4 Inhibitors (Gliptins): (e.g., sitagliptin, saxagliptin, linagliptin, alogliptin) * Mechanism: Inhibit dipeptidyl peptidase-4, prolonging action of endogenous GLP-1 and GIP. * Benefits: Modest A1c reduction, weight-neutral, low hypoglycemia risk. * Side Effects: Nasopharyngitis, headache, joint pain, pancreatitis (rare), heart failure risk (saxagliptin, alogliptin). * Dosage: Once daily, renal dose adjustment for most. Linagliptin does not require renal adjustment. * Sulfonylureas (SUs): (e.g., glipizide, glimepiride, glyburide) * Mechanism: Stimulate insulin secretion from beta cells (insulin secretagogues). * Benefits: Effective A1c reduction, inexpensive. * Side Effects: Hypoglycemia, weight gain. * Dosage: Varies by agent, usually once or twice daily. * Thiazolidinediones (TZDs): (e.g., pioglitazone, rosiglitazone) * Mechanism: PPAR-gamma agonists, increasing insulin sensitivity in peripheral tissues. * Benefits: Effective A1c reduction, durable. Pioglitazone has some evidence for cardiovascular benefit (secondary outcomes). * Side Effects: Weight gain, fluid retention/edema, heart failure exacerbation, bone fractures, bladder cancer (pioglitazone, controversial), macular edema. * Contraindications: NYHA Class III/IV heart failure. * Insulin: Essential for T1DM, and often eventually required for T2DM as beta-cell function declines. * Basal Insulin: Once daily (glargine, detemir, degludec) or twice daily NPH. * Prandial Insulin: Rapid-acting (lispro, aspart, glulisine) or short-acting (regular) before meals. * Mixed Insulin: Pre-mixed insulin (e.g., 70/30 NPH/regular) combines basal and prandial. * Dosage: Highly individualized, titrated based on glucose monitoring. * Side Effects: Hypoglycemia, weight gain. * Alpha-Glucosidase Inhibitors: (e.g., acarbose, miglitol) * Mechanism: Delay carbohydrate absorption in the gut. * Benefits: Reduce postprandial glucose, weight-neutral. * Side Effects: GI (flatulence, abdominal pain, diarrhea). * Amylin Analogs: (e.g., pramlintide) * Mechanism: Synthetic analog of human amylin, co-secreted with insulin. Reduces postprandial glucose by slowing gastric emptying, suppressing glucagon, and increasing satiety. * Usage: Adjunct to insulin in T1DM and T2DM. * Side Effects: Nausea, hypoglycemia (especially when insulin dose not reduced). * Bile Acid Sequestrants: (e.g., colesevelam) * Mechanism: Reduces glucose absorption, mechanism not fully clear. * Usage: Adjunct in T2DM, modest A1c reduction. * Dopamine Agonists: (e.g., bromocriptine) * Mechanism: Modulates hypothalamic circadian rhythm, which may improve insulin sensitivity. * Usage: Adjunct in T2DM, modest A1c reduction.

• Non-pharmacological: Foundation of diabetes management.

  • Medical Nutrition Therapy (MNT): Individualized, provided by a registered dietitian. Focus on healthy eating patterns (e.g., Mediterranean, DASH, plant-based), carbohydrate counting, portion control, limiting added sugars and refined carbohydrates.
  • Physical Activity:
    • Adults: At least 150 minutes/week of moderate-intensity aerobic physical activity, or 75 minutes/week of vigorous-intensity aerobic activity. Spread over at least 3 days/week, with no more than 2 consecutive days without activity.
    • Resistance training: 2-3 times/week on non-consecutive days.
    • Reduce sedentary time.
  • Weight Management:
    • Achieving and maintaining weight loss (e.g., 5-10% of body weight) significantly improves glycemic control and reduces cardiovascular risk.
    • Bariatric surgery: Considered for T2DM with BMI ≥40 kg/m² or BMI ≥35 kg/m² with significant comorbidities, particularly if attempts at medical therapy are unsuccessful.
  • Smoking Cessation: Crucial due to increased cardiovascular risk.
  • Blood Pressure Control: Target <130/80 mmHg for most adults with diabetes and hypertension. (Individualize based on age, comorbidities, and risk). First-line agents often include ACE inhibitors or ARBs.
  • Lipid Management:
    • Statin therapy for most adults with diabetes.
    • Age <40 years + CVD risk factors: Moderate-intensity statin.
    • Age ≥40 years: Moderate-intensity statin.
    • Age ≥40 years + ASCVD or multiple risk factors: High-intensity statin.
    • Consider adding ezetimibe or PCSK9 inhibitor if LDL-C remains elevated despite maximally tolerated statin.
  • Aspirin Therapy:
    • Primary prevention: Low-dose aspirin (75-162 mg/day) may be considered for T2DM patients aged 40-70 years with increased ASCVD risk and low bleeding risk. Not generally recommended below age 40 or above age 70 for primary prevention.
    • Secondary prevention: Low-dose aspirin for all patients with diabetes and a history of ASCVD.
  • Immunizations:
    • Annual influenza vaccine.
    • Pneumococcal vaccines (PCV15 or PCV20; if PCV15, follow with PPSV23).
    • Hepatitis B vaccination (ages 19-59, consider for ≥60 years).
    • RSV vaccine (age ≥60 years).
    • Zoster vaccine (age ≥50 years).

• Monitoring:

  • Self-Monitoring of Blood Glucose (SMBG): Frequency depends on treatment regimen. Essential for insulin users; may be less frequent for those on oral agents not prone to hypoglycemia.
  • Continuous Glucose Monitoring (CGM): Recommended for all individuals on multiple daily injections (MDI) of insulin or insulin pump therapy, and can be beneficial for other individuals to optimize glycemic control. Provides real-time glucose data.
  • Routine Office Visits: Every 3-6 months.
  • Annual Screening for Complications:
    • Comprehensive Foot Exam: Inspection, sensation testing (10-g monofilament), vascular assessment (pulses, ABI if indicated).
    • Dilated Retinal Exam: By ophthalmologist.
    • Urine Albumin-to-Creatinine Ratio (UACR) and eGFR.
    • Dental Exam: Annually.

Treatment Algorithms (T2DM)

Based on ADA/EASD Consensus Report and other major guidelines:

• First-Line:

  1. Metformin: Initiated at diagnosis, if not contraindicated.
  2. Lifestyle Modification: Intensive and ongoing MNT, regular physical activity, weight management.
  3. Early Comprehensive Assessment: At diagnosis, assess for comorbid atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD).

• Second-Line (After Metformin, or if Metformin is contraindicated/not tolerated):

  • If patient has ASCVD, indicators of high ASCVD risk, HF, or CKD:
    • GLP-1 RA or SGLT2 inhibitor with proven cardiovascular and/or renal benefit is recommended.
    • Choice between GLP-1 RA and SGLT2i:
      • ASCVD or high ASCVD risk predominates: GLP-1 RA (liraglutide, semaglutide, dulaglutide) or SGLT2i (empagliflozin, canagliflozin, dapagliflozin).
      • Heart Failure (especially HFrEF): SGLT2i (empagliflozin, dapagliflozin).
      • CKD (eGFR <60 mL/min/1.73m² or albuminuria): SGLT2i (canagliflozin, dapagliflozin, empagliflozin) if eGFR permits initiation. If SGLT2i not tolerated or contraindicated, GLP-1 RA (dulaglutide, semaglutide, liraglutide) with kidney benefit.
      • Consider Finerenone for patients with T2DM and CKD (eGFR 25-75 mL/min/1.73m² and albuminuria) to reduce kidney and CV event risk, as an add-on to RAS blockade.
  • If patient primarily needs to minimize hypoglycemia or promote weight loss:
    • Minimize hypoglycemia: GLP-1 RA, SGLT2i, DPP-4i, TZD. Avoid or use with caution: Sulfonylureas, Glinides, Insulin.
    • Promote weight loss: GLP-1 RA, SGLT2i, Tirzepatide.
  • If cost is a major issue:
    • Sulfonylurea or TZD. (However, prioritize agents with cardiorenal benefits if indicated, even if higher cost).

• Refractory Cases (Intensification):

  • If A1c target not met after 3 months on dual therapy, proceed to triple therapy.
  • If using GLP-1 RA/SGLT2i/DPP-4i/TZD, consider adding insulin (basal first, then basal-bolus).
  • If already on basal insulin, consider intensifying to basal-bolus, or adding a GLP-1 RA.
  • Consider advanced therapies like bariatric surgery for eligible patients with severe obesity and T2DM.
  • Referral to an endocrinologist or diabetes specialist for complex cases.

Complications

Diabetes can affect virtually every organ system. - Common Acute Complications: * Hypoglycemia: Blood glucose <70 mg/dL (3.9 mmol/L). Symptoms include tremors, palpitations, anxiety, sweating, hunger, confusion, dizziness, blurred vision, seizures, coma. Risk is highest with insulin and sulfonylureas. * Diabetic Ketoacidosis (DKA): Severe insulin deficiency leading to hyperglycemia, ketosis, and metabolic acidosis. Characterized by glucose >250 mg/dL, pH <7.3, bicarbonate <18 mEq/L, moderate/large ketonuria/ketonemia. More common in T1DM, but can occur in T2DM. * Hyperosmolar Hyperglycemic State (HHS): Severe hyperglycemia, hyperosmolality, and dehydration, without significant ketoacidosis. Characterized by glucose >600 mg/dL, plasma osmolality >320 mOsm/kg, mild or absent ketonuria/ketonemia. More common in T2DM, often in elderly patients with comorbidities. - Serious Long-term Complications: * Microvascular Complications: * Diabetic Retinopathy: Leading cause of new cases of blindness in adults aged 20-74 years. Non-proliferative (microaneurysms, hemorrhages, hard exudates, cotton wool spots) and proliferative (neovascularization, vitreous hemorrhage, retinal detachment). Diabetic macular edema can occur at any stage. * Diabetic Nephropathy: Leading cause of end-stage kidney disease (ESKD). Characterized by persistent albuminuria (>30 mg/24h or UACR >30 mg/g) and progressive decline in GFR. * Diabetic Neuropathy: * Peripheral Neuropathy: Distal symmetric polyneuropathy (DSPN) is most common (stocking-glove distribution of numbness, tingling, pain, burning, loss of protective sensation). Increases risk of foot ulcers and amputations. * Autonomic Neuropathy: Affects multiple organ systems: * Cardiovascular: Orthostatic hypotension, resting tachycardia, silent ischemia, impaired heart rate variability. * Gastrointestinal: Gastroparesis (nausea, vomiting, early satiety, erratic glucose control), diarrhea, constipation. * Genitourinary: Erectile dysfunction, bladder dysfunction (neurogenic bladder), retrograde ejaculation. * Sudomotor: Anhidrosis or hyperhidrosis. * Macrovascular Complications (Atherosclerotic Cardiovascular Disease - ASCVD): Accelerated atherosclerosis leading to: * Coronary Artery Disease (CAD): Angina, myocardial infarction, heart failure. Often silent in diabetes. * Cerebrovascular Disease: Ischemic stroke, transient ischemic attack (TIA). * Peripheral Artery Disease (PAD): Intermittent claudication, critical limb ischemia, non-healing foot ulcers, amputations. * Diabetic Foot Complications: A combination of neuropathy, PAD, and infection leads to ulcers, Charcot neuroarthropathy, osteomyelitis, and ultimately often necessitates amputation. * Infections: Increased susceptibility to bacterial (skin, UTIs, pneumonia), fungal (candidiasis), and specific opportunistic infections (e.g., mucormycosis, malignant otitis externa) due to impaired immunity and hyperglycemia. * Non-Alcoholic Fatty Liver Disease (NAFLD) / Non-Alcoholic Steatohepatitis (NASH): Highly prevalent in T2DM, can progress to cirrhosis and hepatocellular carcinoma. * Oral Complications: Periodontal disease, gingivitis. * Psychosocial Complications: Increased rates of depression, anxiety, eating disorders, and diabetes distress. * Sexual Dysfunction: Erectile dysfunction in men, decreased libido and dyspareunia in women. * Cancer: Increased risk of certain cancers (liver, pancreas, colon, breast, bladder).

Prognosis

• Factors Affecting Outcome:
  • Glycemic Control: Achieving and maintaining individualized HbA1c targets significantly reduces the risk of microvascular and macrovascular complications. The "legacy effect" or "metabolic memory" suggests early intensive control provides long-term benefits even if control later wanes.
  • Duration of Diabetes: Longer duration of diabetes is associated with higher risk of complications.
  • Presence of Complications at Diagnosis: Indicates advanced disease and worse prognosis.
  • Control of Comorbidities: Effective management of hypertension, dyslipidemia, and obesity substantially improves prognosis.
  • Lifestyle Factors: Adherence to MNT, regular physical activity, and smoking cessation.
  • Socioeconomic Factors: Access to healthcare, medications, healthy food, and education.
• Survival:
  • Diabetes significantly reduces life expectancy. Individuals with T1DM have a life expectancy reduced by an average of 10-15 years. For T2DM, life expectancy is reduced by 5-10 years.
  • Cardiovascular disease is the leading cause of morbidity and mortality in individuals with diabetes.
  • Mortality rates from all causes and from specific cardiovascular causes are significantly higher in people with diabetes compared to those without.
• Quality of Life:
  • Complications such as neuropathy (pain, amputations), nephropathy (dialysis, transplantation), retinopathy (vision loss), and cardiovascular disease severely impair quality of life, leading to physical disability, psychological distress, and reduced functional independence.
  • Diabetes distress, depression, and anxiety are common and further impact well-being.
  • The burden of daily self-management can be significant.

Prevention

• Primary Prevention (Preventing initial occurrence):
  • Target Population: Individuals at high risk for T2DM (e.g., prediabetes, strong family history, history of GDM).
  • Intensive Lifestyle Intervention: As demonstrated by the Diabetes Prevention Program (DPP), a structured program focusing on:
    • Weight Loss: ≥7% of body weight.
    • Physical Activity: ≥150 minutes/week of moderate-intensity activity.
  • Pharmacological Intervention (for select high-risk individuals):
    • Metformin: May be considered for prediabetes, especially in those with BMI ≥35 kg/m², age <60 years, or history of GDM.
• Secondary Prevention (Early detection and intervention):
  • Screening: Regular screening for T2DM in at-risk individuals (overweight/obese adults aged ≥35 years, or with additional risk factors) using FPG, HbA1c, or 2hPG.
  • Early Diagnosis and Treatment: Promptly initiate appropriate management (lifestyle and pharmacological) upon diagnosis to prevent or delay the onset of complications.
• Tertiary Prevention (Preventing complications):
  • Optimized Glycemic Control: Achieve and maintain individualized HbA1c targets.
  • Aggressive Cardiovascular Risk Factor Management:
    • Blood Pressure: Control to target (<130/80 mmHg for most).
    • Lipids: Statin therapy for most, with appropriate LDL-C targets.
    • Antiplatelet Therapy: Aspirin for secondary prevention.
  • Regular Screening for Complications: Annual dilated eye exams, comprehensive foot exams, UACR and eGFR.
  • Early Intervention for Complications: Prompt treatment of retinopathy, nephropathy, neuropathy, and foot problems.
  • Immunizations: Maintain up-to-date vaccinations.
  • Smoking Cessation.

Special Populations

• Pediatric:
  • T1DM: Most common type in children. Management focuses on intensive insulin therapy (basal-bolus or pump), carbohydrate counting, frequent glucose monitoring (often with CGM), and psychosocial support. Glycemic targets individualized, often HbA1c <7.0%. Avoidance of DKA is a primary goal.
  • T2DM: Increasing incidence, often associated with obesity, family history, and minority ethnicity. Management includes lifestyle modification, metformin (first-line), and sometimes insulin or GLP-1 RAs if metformin is insufficient. Screening for complications begins earlier than in adults (e.g., annually for microalbuminuria starting 5 years post-diagnosis or at puberty).
• Geriatric:
  • Individualized Glycemic Targets: Less stringent HbA1c targets (e.g., 7.5-8.0% or even higher) may be appropriate for older adults with limited life expectancy, multiple comorbidities, or high risk of hypoglycemia, to prioritize safety and quality of life over aggressive control.
  • Focus on Hypoglycemia Prevention: Greater vulnerability to severe hypoglycemia, which can lead to falls, fractures, cognitive decline, and cardiovascular events.
  • Management of Comorbidities: High prevalence of hypertension, heart failure, CKD, and cognitive impairment. Polypharmacy is common.
  • Functional Status and Social Support: Assess these factors.
• Pregnancy:
  • Gestational Diabetes Mellitus (GDM):
    • Screening: Universal screening at 24-28 weeks gestation using a 1-step (75-g OGTT) or 2-step approach (50-g glucose challenge test followed by 100-g OGTT if positive).
    • Diagnostic Criteria (75-g OGTT): Fasting ≥92 mg/dL, 1-h ≥180 mg/dL, 2-h ≥153 mg/dL. GDM diagnosed if any value is met or exceeded.
    • Management: MNT and exercise are first-line. Insulin is preferred pharmacological agent if lifestyle fails. Metformin and glyburide may be considered, but insulin is generally safer and more effective.
    • Postpartum: Reclassify 6-12 weeks postpartum with FPG or 75-g OGTT. Women with GDM have a significantly increased lifetime risk of developing T2DM.
  • Pre-existing Diabetes in Pregnancy (T1DM or T2DM):
    • Preconception Care: Optimize glycemic control (HbA1c <6.5%) before conception to minimize congenital anomalies. Discontinue teratogenic medications (e.g., ACE inhibitors, ARBs, statins).
    • Glycemic Targets during Pregnancy: More stringent, e.g., FPG <95 mg/dL, 1-h postprandial <140 mg/dL, 2-h postprandial <120 mg/dL.
    • Insulin: Preferred therapy.
    • Complications: Increased risk of preeclampsia, preterm birth, macrosomia, congenital anomalies, DKA.
• Comorbidities:
  • Heart Failure (HF): SGLT2 inhibitors are strongly recommended for T2DM patients with HF (especially HFrEF) due to significant benefits in reducing HF hospitalizations and cardiovascular mortality. GLP-1 RAs are also beneficial for ASCVD risk reduction.
  • Chronic Kidney Disease (CKD): SGLT2 inhibitors and GLP-1 RAs with proven kidney benefits are recommended to slow CKD progression. Finerenone may also be considered. Insulin dosage requires adjustment with declining kidney function.
  • Obesity: GLP-1 RAs, SGLT2 inhibitors, and tirzepatide are preferred for weight loss benefits. Bariatric surgery is a highly effective treatment for T2DM in severely obese individuals.

Clinical Pearls

• Diagnostic:
  • A single elevated random glucose ≥200 mg/dL with classic symptoms (polyuria, polydipsia, weight loss) is sufficient for diagnosis, no confirmation needed.
  • HbA1c can be affected by conditions altering red blood cell turnover; use glucose-based tests in such situations.
  • Consider specific antibody testing and C-peptide levels to distinguish T1DM from T2DM, especially in lean adults presenting with DKA or suspected LADA (Latent Autoimmune Diabetes in Adults).
• Treatment:
  • Metformin first, but don't delay adding agents with cardiorenal benefits. If a patient with T2DM has established ASCVD, HF, or CKD, add an SGLT2 inhibitor or GLP-1 RA (whichever is appropriate) regardless of A1c or current metformin use.
  • Hypoglycemia is the main limiting factor for intensive glycemic control. Always inquire about and address hypoglycemia.
  • Patient education is paramount. Empower patients with knowledge about their condition, medication, diet, exercise, and self-monitoring.
  • Individualize treatment targets and choices. What's best for one patient may not be for another.
• Pitfalls:
  • Clinical Inertia: Failure to intensify therapy when A1c targets are not met.
  • Over-reliance on HbA1c: Ignoring glucose variability or frequent hypoglycemic events.
  • Ignoring Complications Screening: Neglecting annual foot exams, eye exams, and kidney function monitoring.
  • Not addressing cardiovascular risk comprehensively: Focus solely on glucose, overlooking BP, lipids, and antiplatelet therapy.
  • Not assessing psychosocial factors: Depression, anxiety, and diabetes distress significantly impact adherence and outcomes.
  • Stopping metformin unnecessarily for mild renal impairment: Metformin can often be continued with caution down to eGFR 30 mL/min/1.73m², with dose adjustment.

Recent Updates

• Guidelines: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes are updated annually, providing comprehensive, evidence-based recommendations. The European Association for the Study of Diabetes (EASD) also issues joint consensus reports.
• Evidence:
  • Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Robust evidence from large cardiovascular outcomes trials (CVOTs) has solidified their role as cornerstone therapies in T2DM patients with ASCVD, HF, or CKD, irrespective of baseline glycemic control.
  • Dual GIP/GLP-1 Receptor Agonists: Tirzepatide has shown superior A1c and weight reduction compared to GLP-1 RAs alone in clinical trials, with CVOTs ongoing.
  • Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone): Approved for T2DM and CKD to reduce the risk of sustained eGFR decline, ESKD, cardiovascular death, nonfatal MI, and HF hospitalization.
  • Improved Technologies: Continuous Glucose Monitoring (CGM) systems are becoming more accurate, affordable, and widely used, improving glycemic management and reducing hypoglycemia. Automated insulin delivery systems (hybrid closed-loop systems) are advancing rapidly for T1DM.
• Controversies:
  • Optimal Glycemic Targets in the Elderly: Balancing the benefits of glycemic control against the risks of hypoglycemia and treatment burden.
  • Aspirin for Primary Prevention: Ongoing debate regarding the net benefit in patients with diabetes without established ASCVD, given the bleeding risk.
  • Role of Very Low-Carbohydrate Diets: Effectiveness and long-term safety, especially regarding cardiovascular risk factors, are still being studied.

Key References

• Guidelines:
  • American Diabetes Association (ADA): Standards of Medical Care in Diabetes. Published annually in Diabetes Care. (Most comprehensive and widely used clinical guideline).
  • European Association for the Study of Diabetes (EASD): Joint consensus reports with the ADA on various aspects of diabetes management.
  • American Association of Clinical Endocrinology (AACE): Clinical practice guidelines for the management of diabetes.
  • National Institute for Health and Care Excellence (NICE): Clinical guidelines for diabetes (UK).
• Studies (Landmark):
  • Diabetes Control and Complications Trial (DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC): Established the benefits of intensive glycemic control in T1DM.
  • UK Prospective Diabetes Study (UKPDS): Demonstrated the benefits of intensive glycemic control and blood pressure control in T2DM.
  • EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, VERTIS CV: Cardiovascular outcomes trials for SGLT2 inhibitors demonstrating cardiovascular and renal benefits.
  • LEADER, SUSTAIN-6, REWIND, PIONEER 6: Cardiovascular outcomes trials for GLP-1 Receptor Agonists demonstrating cardiovascular benefits.
  • DPP (Diabetes Prevention Program): Demonstrated the effectiveness of lifestyle intervention and metformin in preventing T2DM.
  • FIDELIO-DKD, FIGARO-DKD: Trials on finerenone for T2DM and CKD.
• Reviews:
  • UpToDate, Medscape, NEJM, The Lancet Diabetes & Endocrinology: Peer-reviewed journals and clinical reference tools provide up-to-date reviews and research.